Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

English version České info

The mosquito-borne dengue viruses (DENV) are responsible for approximately 390 million new infections worldwide each year, and an estimated 100 million of these infections lead to clinical disease. The presence of four different serotypes of DENV allows the same individual to experience more than one DENV infection. Secondary DENV infections with a different serotype are more likely to cause severe dengue disease than primary infections. One of the explanations for the greater risk of severe disease during secondary DENV infections is the phenomenon called antibody-dependent enhancement (ADE), where pre-existing DENV-specific antibodies enable entry of DENV into target host cells, and thereby enhance infection and disease. At the moment, the epitopes targeted by enhancing antibodies following a DENV infection are unclear. In the present study, we use novel techniques to fractionate human serum antibodies and test their ability to enhance DENV infection both in vitro (K562 cells) and in vivo (in a mouse model of lethal antibody-enhanced dengue disease). We found that antibodies binding both the envelope and prM proteins on the DENV virion play an important role in ADE of DENV by human immune sera. Our findings about DENV-enhancing antibodies in human immune sera are relevant to developing safe vaccines.

Vyšlo v časopise: Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera. PLoS Pathog 10(10): e32767. doi:10.1371/journal.ppat.1004386
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004386

Souhrn

Zdroje

1. GuzmanMG, HalsteadSB, ArtsobH, BuchyP, FarrarJ, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7–16.

2. MackeyTK, LiangBA (2012) Threats from emerging and re-emerging neglected tropical diseases (NTDs). Infect Ecol Epidemiol 2: 10.3402/iee.v3402i3400.18667.

3. BhattS, GethingPW, BradyOJ, MessinaJP, FarlowAW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507.

4. VaughnDW, GreenS, KalayanaroojS, InnisBL, NimmannityaS, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2–9.

5. HalsteadSB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421–467.

6. HalsteadSB, NimmannityaS, CohenSN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311–328.

7. ChauTN, QuyenNT, ThuyTT, TuanNM, HoangDM, et al. (2008) Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516–524.

8. KliksSC, NimmanityaS, NisalakA, BurkeDS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.

9. ChauTN, HieuNT, AndersKL, WolbersM, Lien leB, et al. (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200: 1893–1900.

10. Rodenhuis-ZybertIA, van der SchaarHM, da Silva VoorhamJM, van der Ende-MetselaarH, LeiHY, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718.

11. UbolS, HalsteadSB (2010) How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829–1835.

12. ChareonsirisuthigulT, KalayanaroojS, UbolS (2007) Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 88: 365–375.

13. BoonnakK, DambachKM, DonofrioGC, TassaneetrithepB, MarovichMA (2011) Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol 85: 1671–1683.

14. KouZ, LimJY, BeltramelloM, QuinnM, ChenH, et al. (2011) Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 410: 240–247.

15. RolphMS, ZaidA, RulliNE, MahalingamS (2011) Downregulation of interferon-beta in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. J Infect Dis 204: 489–491.

16. HalsteadSB, ShotwellH, CasalsJ (1973) Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128: 15–22.

17. GoncalvezAP, EngleRE, St ClaireM, PurcellRH, LaiCJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422–9427.

18. UbolS, PhukliaW, KalayanaroojS, ModhiranN (2010) Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923–935.

19. ModhiranN, KalayanaroojS, UbolS (2010) Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis 4: e924.

20. SchlesingerRW (1977) Dengue viruses. Virol Monogr 1–132.

21. RautCG, DeolankarRP, KolhapureRM, GoverdhanMK (1996) Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 40: 143–146.

22. JohnsonAJ, RoehrigJT (1999) New mouse model for dengue virus vaccine testing. J Virol 73: 783–786.

23. ZellwegerRM, PrestwoodTR, ShrestaS (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128–139.

24. ShrestaS, ShararKL, PrigozhinDM, BeattyPR, HarrisE (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208–10217.

25. BalsitisSJ, WilliamsKL, LachicaR, FloresD, KyleJL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.

26. BeltramelloM, WilliamsKL, SimmonsCP, MacagnoA, SimonelliL, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271–283.

27. de AlwisR, BeltramelloM, MesserWB, Sukupolvi-PettyS, WahalaWM, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188.

28. DejnirattisaiW, JumnainsongA, OnsirisakulN, FittonP, VasanawathanaS, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745–748.

29. SmithSA, ZhouY, OlivarezNP, BroadwaterAH, de SilvaAM, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86: 2665–2675.

30. SmithSA, de AlwisR, KoseN, DurbinAP, WhiteheadSS, et al. (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Journal of Infectious Diseases 207: 1898–1908.

31. de AlwisR, SmithSA, OlivarezNP, MesserWB, HuynhJP, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109: 7439–7444.

32. RoehrigJT, BolinRA, KellyRG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.

33. SmithSA, de AlwisAR, KoseN, HarrisE, IbarraKD, et al. (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4: e00873–00813.

34. LaiCY, TsaiWY, LinSR, KaoCL, HuHP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631–6643.

35. LaiCY, WilliamsKL, WuYC, KnightS, BalmasedaA, et al. (2013) Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7: e2451.

36. LuoYY, FengJJ, ZhouJM, YuZZ, FangDY, et al. (2013) Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC Microbiol 13: 194.

37. ChanAH, TanHC, ChowAY, LimAP, LokSM, et al. (2012) A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS One 7: e33451.

38. LiL, LokSM, YuIM, ZhangY, KuhnRJ, et al. (2008) The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830–1834.

39. SongKY, ZhaoH, LiSH, LiXF, DengYQ, et al. (2013) Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus. J Gen Virol 94: 1510–1516.

40. WilliamsKL, Sukupolvi-PettyS, BeltramelloM, JohnsonS, SallustoF, et al. (2013) Therapeutic efficacy against lethal dengue virus infection of antibodies lacking Fcγreceptor binding is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog 9: e1003157.

41. JunjhonJ, EdwardsTJ, UtaipatU, BowmanVD, HoldawayHA, et al. (2010) Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 84: 8353–8358.

42. TeohEP, KukkaroP, TeoEW, LimAP, TanTT, et al. (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4: 139ra183.

43. VanblarganLA, MukherjeeS, DowdKA, DurbinAP, WhiteheadSS, et al. (2013) The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9: e1003761.

44. MesserWB, de AlwisR, YountBL, RoyalSR, HuynhJP, et al. (2014) Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A 111: 1939–1944.

45. LittauaR, KuraneI, EnnisFA (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183–3186.

46. RodrigoWW, JinX, BlackleySD, RoseRC, SchlesingerJJ (2006) Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 80: 10128–10138.

47. ChanKR, ZhangSL, TanHC, ChanYK, ChowA, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479–12484.

48. BoonnakK, SlikeBM, DonofrioGC, MarovichMA (2013) Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190: 5659–5665.

49. BruhnsP, IannascoliB, EnglandP, MancardiDA, FernandezN, et al. (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716–3725.

50. BruhnsP (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640–5649.

51. GarciaG, SierraB, PerezAB, AguirreE, RosadoI, et al. (2010) Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg 82: 1153–1156.

52. PrestwoodTR, PrigozhinDM, ShararKL, ZellwegerRM, ShrestaS (2008) A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82: 8411–8421.

53. WahalaWM, KrausAA, HaymoreLB, Accavitti-LoperMA, de SilvaAM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103–113.

54. LinHE, TsaiWY, LiuIJ, LiPC, LiaoMY, et al. (2012) Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis 6: e1447.

55. WilliamsKL, WahalaWM, OrozcoS, de SilvaAM, HarrisE (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

56. OrozcoS, SchmidMA, ParameswaranP, LachicaR, HennMR, et al. (2012) Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93: 2152–2157.